Inveniai LLC and Kyowa Kirin Co. Ltd. have expanded their partnership a second time, inking their most recent multiple drug discovery agreement. The multiyear deal will see the duo discover novel targets and treatments for therapeutic areas across Kyowa Kirin’s portfolio and areas of interest using Inveniai’s artificial intelligence (AI) platform.
Prism Biolab Co. Ltd. has added Genentech Inc., a unit of Roche Holding AG, to the list of users for its peptide mimetic small-molecules library after signing a multitarget research collaboration and licensing agreement. Under the agreement, Tokyo-based Prism Biolab will open its Pepmetics Library, a library of peptide mimetic small molecules, to screen against targets selected by Roche and Genentech.
Inveniai LLC and Kyowa Kirin Co. Ltd. have expanded their partnership a second time, inking their most recent multiple drug discovery agreement. The multiyear deal will see the duo discover novel targets and treatments for therapeutic areas across Kyowa Kirin’s portfolio and areas of interest using Inveniai’s artificial intelligence (AI) platform.
Nec Corp. has inked a global partnership agreement with Bostongene Corp. that will bring the latter’s Bostongene Tumor Portrait Tests to Japanese patients. Japan is the first market outside of the U.S. for the tests, according to the companies.
Japan’s Astellas Pharma Inc. is continuing its investment in gene therapies, following up its $3 billion acquisition of Audentes Therapeutics Inc. with a technology licensing deal with Dyno Therapeutics Inc. potentially worth more than $1.6 billion. Central to the deal is Cambridge, Mass.-based Dyno’s adeno-associated virus (AAV) vector technology, which can be used to direct gene therapies to skeletal and cardiac muscle.
Japan’s Astellas Pharma Inc. is continuing its investment in gene therapies, following up its $3 billion acquisition of Audentes Therapeutics Inc. with a technology licensing deal with Dyno Therapeutics Inc. potentially worth more than $1.6 billion. Central to the deal is Cambridge, Mass.-based Dyno’s adeno-associated virus (AAV) vector technology, which can be used to direct gene therapies to skeletal and cardiac muscle.
Following an FDA priority review, Takeda Pharmaceutical Co. Ltd.'s oral antiviral, maribavir, has won U.S. approval as the first drug in the country to treat resistant cytomegalovirus (CMV) infection and disease in adult and pediatric transplant recipients. The drug will be marketed as Livtencity.
Following an FDA priority review, Takeda Pharmaceutical Co. Ltd.'s oral antiviral, maribavir, has won U.S. approval as the first drug in the country to treat resistant cytomegalovirus (CMV) infection and disease in adult and pediatric transplant recipients. The drug will be marketed as Livtencity.
Top-line results of Daiichi Sankyo Co. Ltd.’s phase III Quantum-First study, testing the addition of quizartinib to chemotherapy vs. chemotherapy alone for adults with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML), found the combination therapy provided a “statistically significant and clinically meaningful improvement” in overall survival vs. standard treatment alone, meeting the trial’s primary endpoint, Ken Takeshita, global head of R&D at Daiichi Sankyo, told BioWorld.
LONDON – Sosei Heptares is to get $100 million up front in a potential $2.6 billion deal with Neurocrine Biosciences Inc., in which the pair will develop muscarinic receptor agonists in the treatment of schizophrenia, dementia and other neuropsychiatric disorders. San Diego-based Neurocrine is taking rights to a portfolio of small molecules against specific subtypes of the muscarinic receptor family, targeting M1 and M4 alone, plus a dual M1/M4 agonist.
RSS
